How high glucose levels affect T cell therapies for cancer
Functional consequences of high glucose culture on adoptive T cell therapies for cancer
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11069146
This study is looking at how high sugar levels in the body might affect special immune cells called T cells that are used in cancer treatments, with the goal of making these treatments work better for patients with solid tumors.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11069146 on ClinicalTrials.gov |
What this research studies
This research investigates the impact of high glucose levels on T cells used in cancer treatments, specifically focusing on adoptive cell therapy (ACT). ACT involves taking T cells from a patient, modifying them to better fight cancer, and then reintroducing them into the patient. The study examines how the high glucose environment during the T cell expansion process affects their ability to respond to cancer cells. By understanding these effects, the research aims to improve the effectiveness of T cell therapies for solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing or considering adoptive T cell therapy for solid tumors.
Not a fit: Patients with hematological malignancies may not benefit directly from this research as it focuses on solid tumors.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of T cell therapies, leading to better outcomes for cancer patients.
How similar studies have performed: Other research has shown that optimizing the culture conditions for T cells can improve their functionality, suggesting that this approach may lead to significant advancements.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BUMGARNER, HANNAH — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: BUMGARNER, HANNAH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy